慢性乙型肝炎患者病毒载量与疾病状态和治疗策略选择*

doi:10.3969/j.issn.1672-5069.2023.05.002

Abstract

Zhang Dan, Ding Yang. Serum viral loads-oriented disease status and antiviral strategies in patients with chronic hepatitis B viral infection[J]. Journal of Practical Hepatology, 2023, 26(5): 612-614.

References

[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39.
[2] Yuan J, Lu ZK, Xiong X,et al. Impact of national volume-based procurement on the procurement volumes and spending for antiviral medications of hepatitis B virus. Front Pharmacol, 2022, 13:842944.
[3] 中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见. 中华肝脏病杂志, 2022, 30(2): 131-136.
[4] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67(2):370-398.
[5] Gordon SC, Krastev Z, Horban A, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology, 2013, 58(2):505-513.
[6] Chan HLY, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg positive chronic hepatitis B virus infection: a randomized, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016, 1(3):185-195.
[7] Lin MH, Li HQ, Zhu L, et al. Liver fibrosis in the natural course of chronic hepatitis B viral infection: a systematic review with meta-analysis. Dig Dis Sci, 2022, 67(6):2608-2626.
[8] Kim GA, Lim YS, Han S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut, 2018, 67(5):945-952.
[9] 赵素贤, 常楚笛, 南月敏. 精准免疫分期指导慢性HBV感染者尽早启动抗病毒治疗. 中华肝脏病杂志, 2023, 31(3):228-232.
[10] Lee H, Jang S, Ahn SH, et al. Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level<2000 IU/mL. Hepatol Int, 2022,16(2):294-305.
[11] Huang DQ, Tamaki N, Lee HW, et al. Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis. Hepatology, 2023, 77(5):1746-1756.
[12] Wong RJ, Kaufman HW, Niles JK, et al. Simplifying treatment criteria in chronic hepatitis B: reducing barriers to elimination. Clin Infect Dis, 2023, 76(3):e791-e800.
[13] Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med, 2006, 354(10):1001-1010.
[14] Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol, 2018, 68(4):672-681.
[15] Buti M, Gane E, Seto WK, et al. TAF vs. tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016,1(3):196-206.
[16] Chan HL, Fung S, Seto WK, et al. TAF vs. tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol,2016, 1(3):185-195.
[17] Liu Z, Jin Q, Zhang Y,et al. 96-week treatment of tenofovir amibufenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients. J Clin Transl Hepatol, 2023, 11(3):649-660.
[18] Ning Q, Han M, Sun Y, et al. Switching from entecavir to pegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol, 2014, 61(4):777-784.
[19] Hu P, Shang J, Zhang W, et al. HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: new switch study. J Clin Transl Hepatol, 2018, 6(1): 25-34.
[20] 程齐齐, 杨丽霞, 蔡天盼,等. 核苷(酸)类似物初治的慢性乙型肝炎患者发生低病毒血症的影响因素及其动态变化分析. 临床肝胆病杂志, 2022, 38(12): 2716-2722.
[21] Zhang Q, Peng H, Liu X, et al. Chronic hepatitis B infection withlow level viremia correlates with the progression of the liver disease. J Clin Transl Hepatol, 2021, 9(6):850-859.
[22] Sun Y, Wu X, Zhou J,et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy. Clin Gastroenterol Hepatol, 2020, 18(11):2582-2591,e6.
[23] Kim JH, Sinn DH, Kang W,et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology, 2017, 66(2):335-343.
[24] Lee SB, Jeong J, Park JH, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin Mol Hepatol. 2020,26(3):364-375.
[25] Zhang Q, Cai DC, Hu P,et al. Low-level viremia in nucleoside analog-treated chronic hepatitis B patients. Chin Med J (Engl), 2021, 134(23):2810-2817.
[26] Li ZB, Li L, Niu XX,et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. Liver Int, 2021, 41(6):1254-1264.

Serum viral loads-oriented disease status and antiviral strategies in patients with chronic hepatitis B viral infection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Sheng Qiuju, Dou Xiaoguang. Therapeutic strategies and benefit evaluation in patients with chronic hepatitis B viral infection [J]. Journal of Practical Hepatology, 2023, 26(5): 609-611.
[2]	Peng Zhen, Ning Huibin, Li Kuan, et al. Infection staging and antiviral strategy in individuals with chronic serum HBeAg-positive hepatitis B viral infection [J]. Journal of Practical Hepatology, 2023, 26(5): 615-617.
[3]	Huang Baisheng, Ou Lanxin, Zhang Yinjie, et al. Diagnostic performance of FibroScan and GPR, APRI and FIB-4 for liver fibrosis evaluation in patients with chronic hepatitis B virus infection without serum alanine aminotransferase elevation [J]. Journal of Practical Hepatology, 2023, 26(5): 618-621.
[4]	Wu Yulong, Zhuang Jianqi, Liu Zhicheng, et al. Changes of serum HBV pgRNA levels in patients with chronic hepatitis B receiving nucleos(t)ide analogues treatment [J]. Journal of Practical Hepatology, 2023, 26(5): 622-625.
[5]	Wang Yizhuo, Zhang Weiqi, Li Hong. A 3-year follow-up of patients with serum HBeAg-positive chronic hepatitis B after 48 to 72 week pegylated interferon α-2a treatment [J]. Journal of Practical Hepatology, 2023, 26(5): 626-629.
[6]	Hao Anhua, Du Zhongcai, Zhou Lin, et al. Changes of liver stiffness measurement and S index in patients with chronic hepatitis B and their performance in evaluating liver fibrosis [J]. Journal of Practical Hepatology, 2023, 26(5): 630-633.
[7]	Liu Aihua, Fu Jian, Chen Xiaohong. Predicting performance of liver stiffness measurement and GGT/PLT ratio combination in judging liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(5): 634-637.
[8]	Zhou Keli, Lyu Xiaoli, Zhou Yang, et al. Concordance between liver biopsy,and the liver stiffness measurement and hemodynamic index combination for the diagnosis of hepatic fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(4): 480-483.
[9]	Tang Xinhua, Tang Huijing, Huang Chengjun, et al. Preventive effect of entecavir on anti-tuberculosis drug-induced liver injury in patients with pulmonary tuberculosis and serum HBeAg-positive high HBV loads [J]. Journal of Practical Hepatology, 2023, 26(4): 516-519.
[10]	Jiao Yubing, Li Ling, Huang Xinhui, et al. Impact of low-level viremia on prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after TACE therapy [J]. Journal of Practical Hepatology, 2023, 26(4): 548-551.
[11]	Liu Ying, Chen Dongmiao, Wang Congrong. Implications of serum adenosine deaminase, α-L-fucosidase and alpha fetoprotein-L3 levels in patients with chronic hepatitis B, liver cirrhosis and primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(4): 552-555.
[12]	Tao Zhenzhen, Wang Yongli, Sun Hongyan, et al.. Comparison of different Young's modulus determination by two-dimensional shear wave elastography in predicting liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 328-331.
[13]	Zhao Jing, He Xiubo, Chen Jinhuan. Early diagnosis of significant liver fibrosis by liver shear wave elastography and GGT/PLT ratio in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 332-335.
[14]	Zhang Danlei, Xu Jing. Early antiviral efficacy of tenofovir amibufenamide in treatment of naïve patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 336-339.
[15]	Guo Xiaoling, Zhang Yaowu, Li Mengtao, et al.. Auxiliary treatment of a herbal compound, Ganshuang granule, with entecavir for patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 340-343.